Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picks3i Group Regulatory News (III)

Share Price Information for 3i Group (III)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,891.00
Bid: 2,879.00
Ask: 2,881.00
Change: 49.00 (1.72%)
Spread: 2.00 (0.069%)
Open: 2,853.00
High: 2,891.00
Low: 2,846.00
Prev. Close: 2,842.00
III Live PriceLast checked at -
3i Group is an Investment Trust

To provide its shareholders with quoted access to private equity and infrastructure returns, its main focus is on making quoted and unquoted equity and/ or debt investments in businesses and funds in Europe, Asia and the Americas.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FY2019 Q1 performance update

25 Jul 2018 07:00

RNS Number : 6483V
3i Group PLC
25 July 2018
 

25 July 2018

 

3i Group plc

FY2019 Q1 performance update

 

A good start to the year

 

· NAV per share of 760 pence and total return of 5.1% for the three months to 30 June 2018

 

· Cash realisations of £337 million in the quarter, net of the £535 million reinvestment in Scandlines

 

· Completed two new Private Equity investments in Royal Sanders and International Cruise and Excursions ("ICE") totalling £245 million

 

· Advised 3i Infrastructure plc ("3iN") on its investment in Attero and a further investment for Infinis, Alkane Energy

 

Simon Borrows, Chief Executive, commented:

 

"This was another productive quarter for 3i with good portfolio performance as well as significant investment and realisation activity. We completed the Group's sale and reinvestment into Scandlines, two new Private Equity investments and advised 3iN on its investments in Attero and Alkane Energy. Our balance sheet is strong but we remain cautious about the pricing of new investments in the current environment. Overall, our portfolio of international companies remains well positioned, despite the macro uncertainties, to deliver another year of good earnings growth."

 

 

Private Equity

Portfolio performance

The Private Equity portfolio generated good returns in the quarter. The majority of the portfolio performed well with notable value growth increases from Action, Basic-Fit, Cirtec Medical and Etanco.

 

Private Equity investments

We completed our £135 million investment in Royal Sanders, a private label and contract manufacturing producer of personal care products, in April 2018. In June 2018, we completed our £110 million investment in ICE, a global travel and loyalty company that connects leading brands, travel suppliers and end consumers. In addition to our proprietary investment, we continue to originate acquisition opportunities for our portfolio companies. In the quarter, Royal Sanders announced its first acquisition under our ownership and there is a good pipeline of other acquisition opportunities across the portfolio, the majority of which are expected to be funded by the companies themselves.

 

 

Private Equity realisations

We generated total cash proceeds in the quarter of £868 million, principally from the £835 million received from the sale of Scandlines in June 2018, before taking account of the Group's £535 million reinvestment.

 

Private Equity

 Realisation proceeds

 

£m

Full realisations

 

 

Scandlines1

835

 

SLR

30

Partial realisations

 

 

Other

3

Total Q1 2019 cash proceeds

868

1. Private Equity proceeds are shown gross and before the Group's £535 million reinvestment.

In June 2018, we announced the realisation of Etanco, one of the last investments in Eurofund V, for proceeds of c.€102 million. At 30 June 2018, Etanco was held on an imminent sales basis and valued at £88 million, an uplift of 32% compared to its value at 31 March 2018 of £66 million.

 

Infrastructure

Our Infrastructure team had a busy start to the year, including advising 3iN on the completion of its investments in Attero and Alkane Energy and its refinancing of TCR. 3iN's shares performed well in the quarter, generating unrealised value growth of £27 million for 3i in addition to dividend income of £11 million.

The infrastructure market remains very active and our Infrastructure team is working on a pipeline of interesting investment opportunities in Europe and North America.

Total return and NAV position

 

We recognised a £99 million gain on foreign exchange in the quarter, as both the US dollar and euro strengthened against sterling. Based on the balance sheet at 30 June 2018, a 1% movement in the euro and US dollar would result in a total return movement of £47 million and £10 million respectively. The diluted NAV per share increased to 760 pence (31 March 2018: 724 pence) or 738 pence after deducting the 22p per share FY2018 dividend, which was paid on 20 July 2018.

Balance sheet

 

Top 10 investments by value at 30 June 2018

 

 

 

Valuation

Valuation

 

 

Valuation

Valuation

Mar-18

Jun-18

 

 

basis

currency

£m

£m

Activity in the quarter

Action

Earnings

EUR

2,064

2,215

 

3i Infrastructure plc

Quoted

GBP

581

604

Ex-dividend 14 June 2018

Scandlines

Price of recent investment

EUR

803

539

Full realisation and 3i's partial reinvestment completed on 21 June 2018 and generated net proceeds of £300m

Basic-Fit

Quoted

EUR

270

334

 

Weener Plastics

Earnings

EUR

244

248

 

Audley Travel

Earnings

GBP

233

238

 

Q Holding

Earnings

USD

229

235

 

Cirtec Medical

Earnings

USD

190

219

 

Hans Anders

Earnings

EUR

189

191

 

Smarte Carte

DCF

USD

167

179

Received refinancing proceeds of £4m

The 10 investments in this table comprise 72% (31 March 2018: 75%) of the total Proprietary Capital portfolio value of £6,915 million (31 March 2018: £6,657 million).

 

Balance sheet

 

At 30 June 2018, the Group's balance sheet included net cash of £638 million, before the 22 pence FY2018 dividend (£213 million), which was paid on 20 July 2018.

 

- ENDS -

 

Notes

 

1.

Balance sheet values are stated net of foreign exchange translation. Where applicable, the GBP equivalents at 30 June in this update have been calculated at a currency exchange rate of €1.1310:£1 and $1.3201:£1 respectively. At 30 June 2018, 64% of the Group's net assets were in euro and 14% were in US dollar.

2.

At 30 June 2018 3i had 973 million diluted shares.

3.

Action was valued using a post discount run-rate EBITDA multiple of 16.5x based on its run-rate earnings to 30 June 2018.

 

 

For further information, please contact:

Silvia SantoroInvestor Relations DirectorTel: 020 7975 3258

Kathryn van der Kroft

Communications DirectorTel: 020 7975 3021

 

About 3i Group

3i is a leading international investment manager focused on mid-market Private Equity and Infrastructure. Our core investment markets are northern Europe and North America. For further information, please visit: www.3i.com.

 

All statements in this performance update relate to the three month period ended 30 June 2018 unless otherwise stated. The financial information is unaudited and is presented on 3i's non-GAAP Investment basis in order to provide users with the most appropriate description of the drivers of 3i's performance. Net asset value ("NAV") and total return are the same on the Investment basis and on an IFRS basis. Details of the differences between 3i's consolidated financial statements prepared on an IFRS basis and under the Investment basis are provided in the 2018 Annual report and accounts. There have been no material changes to the financial position of 3i from the end of this quarter to the date of this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTUSUBRWNABUAR
Date   Source Headline
1st May 20248:58 amRNSDirector/PDMR Shareholding
30th Apr 20244:34 pmRNSTotal Voting Rights
2nd Apr 20248:01 amRNSPortfolio Update
28th Mar 20241:02 pmRNSTotal Voting Rights
28th Mar 20241:00 pmRNSDirector/PDMR Shareholding
21st Mar 20241:53 pmRNSDirector/PDMR Shareholding
21st Mar 20247:00 amRNSAction Capital Markets Seminar & portfolio update
1st Mar 202410:11 amRNSDirector/PDMR Shareholding
29th Feb 20244:21 pmRNSTotal Voting Rights
1st Feb 20247:00 amRNS3i Group plc - Q3 performance update
31st Jan 20244:17 pmRNSTotal Voting Rights
31st Jan 20244:14 pmRNSDirector/PDMR Shareholding
4th Jan 20243:36 pmRNSTotal Voting Rights
4th Jan 20243:35 pmRNSDirector/PDMR Shareholding
3rd Jan 202412:00 pmRNSPortfolio Update
8th Dec 20231:11 pmRNSBlock listing Interim Review
30th Nov 20234:55 pmRNSTotal Voting Rights
30th Nov 20234:51 pmRNSDirector/PDMR Shareholding
23rd Nov 202311:11 amRNSDirector Declaration
20th Nov 20239:13 amRNSDirector Declaration
9th Nov 20232:29 pmRNSDirector/PDMR Shareholding
9th Nov 202311:49 amRNSDoc re. Half Yearly Report 2023
9th Nov 20237:00 amRNSHalf-year Report
31st Oct 20233:29 pmRNSTotal Voting Rights
31st Oct 20233:27 pmRNSDirector/PDMR Shareholding
2nd Oct 202312:58 pmRNSDirector/PDMR Shareholding
2nd Oct 202310:36 amRNSPortfolio Update
28th Sep 20231:35 pmRNSDirector/PDMR Shareholding
20th Sep 20237:00 amRNSUpdate on portfolio and Capital Markets Seminar
12th Sep 202310:43 amRNSDirector/PDMR Shareholding
4th Sep 202310:41 amRNSDirector/PDMR Shareholding
31st Aug 20233:56 pmRNSTotal Voting Rights
31st Aug 20233:52 pmRNSDirector/PDMR Shareholding
1st Aug 202311:40 amRNSDirector/PDMR Shareholding
31st Jul 20234:31 pmRNSTotal Voting Rights
31st Jul 20234:27 pmRNSDirector/PDMR Shareholding
20th Jul 20237:00 amRNSFY2024 Q1 performance update
3rd Jul 202310:25 amRNSPortfolio Update
30th Jun 20233:43 pmRNSTotal Voting Rights
30th Jun 20233:37 pmRNSDirector/PDMR Shareholding
30th Jun 202311:01 amRNSDirector/PDMR Shareholding
29th Jun 20235:00 pmRNSDirectorate Change
29th Jun 20233:46 pmRNSDirector/PDMR Shareholding
29th Jun 20233:31 pmRNSDoc re. AGM Resolutions
29th Jun 20233:30 pmRNSResult of AGM
29th Jun 20237:00 amRNSAGM and portfolio update
28th Jun 20232:34 pmRNSDirector/PDMR Shareholding
12th Jun 20232:33 pmRNSPublication of a Prospectus
9th Jun 20239:44 amRNSBlock listing Interim Review
8th Jun 20232:51 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.